News Release

Suven Life Sciences secures 4 (four) Product Patents for their NCEs in China,
Mexico and South Africa
HYDERABAD, INDIA (July 13, 2015) Suven Life Sciences Ltd (Suven) announced today that
they secured patents in China (CN103443093) and South Africa (2013/01143, 2013/06328) to
their New Chemical Entities (NCEs) for CNS therapy through mechanism of action H3 Inverse
agonist and these patents are valid until 2031,2030 and 2031 respectively. The granted claims
of the patent include the class of selective H3 ligands discovered by Suven and are being
developed as therapeutic agents and are useful in the treatment of cognitive impairment
associated with neurodegenerative disorders.
Suven also secured a patent for their NCE in Mexico (326651) and the granted claims of this
patent include the class of selective alpha-4-beta-2 compounds discovered by Suven and are
being developed as therapeutic agents for major depressive disorder (MDD) and the patent is
valid through 2030.
With these new patents, Suven has a total of sixteen (16) granted patents from China, nineteen
(19) granted patents from Mexico and twenty two (22) granted patents from South Africa.
These granted patents are exclusive intellectual property of Suven and are achieved through the
internal discovery research efforts. Products out of these inventions may be out-licensed at
various phases of clinical development like at Phase-I or Phase-II.
We are very pleased by the grant of these patents to Suven for our pipeline of molecules in
CNS arena that are being developed for cognitive disorders with high unmet medical need with
huge market potential globally says Venkat Jasti, CEO of Suven.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and
commercializing novel pharmaceutical products, which are first in class or best in class CNS
therapies through the use of GPCR targets. The Company has eleven (11) internally-discovered
therapeutic drug candidates currently in pre-clinical stage of development targeting conditions
such as ADHD, dementia, depression, Huntingtons disease, Parkinsons disease and obesity in
addition to Phase 2 ready developmental candidate SUVN-502 for and Phase1 candidate SUVNG3031 for Alzheimers disease and Schizophrenia.
For more information please visit our Web site at http://www.suven.com
Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including
expectations and assumptions, contained in this news release may be forward-looking statements that
involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these
forward-looking statements, it is possible that future circumstances might differ from the assumptions on
which such statements are based. Other important factors which could cause results to differ materially
including outsourcing trends, economic conditions, dependence on collaborative partnership programs,
retention of key personnel, technological advances and continued success in growth of sales that may
make our products/services offerings less competitive; Suven may not undertake to update any forwardlooking statements that may be made from time to time.

Suven Life Sciences Limited

C IN : L 2 41 1 0TG 1 98 9P L C 00 9 71 3
Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor I
Road No.5 I Avenue 7 I Banjara Hills I Hyderabad 500 034 I Telangana I India
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com